SARS-CoV-2 Sequencing for Variant Surveillance.

Julie Woolworth Hirschhorn, Jaclyn Dunne
Author Information
  1. Julie Woolworth Hirschhorn: Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC, USA. woolworj@musc.edu. ORCID
  2. Jaclyn Dunne: College of Graduate Studies, Medical University of South Carolina, Charleston, SC, USA.

Abstract

In this chapter, next-generation sequencing of the entire viral genome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is described. Successful sequencing of the SARS-CoV-2 virus is dependent upon quality of the specimen, adequate coverage of the entire genome, and up-to-date annotation. Some of the advantages of performing SARS-CoV-2 surveillance using next-generation sequencing are scalability, high-throughput, cost, and full genome analysis. Some of the disadvantages can be expensive instrumentation, large upfront reagent and supply costs, increased time-to-result, computational needs, and complicated bioinformatics. This chapter will provide an overview of a modified FDA Emergency Use Authorization procedure for the genomic sequencing of SARS-CoV-2. The procedure is also referred to as the research use only (RUO) version.

Keywords

References

  1. World Health Organization (2020) Coronavirus disease (COVID-19): virus evolution. https://www.who.int/news-room/questions-and-answers/item/sars-cov-2-evolution . Accessed July 7, 2022
  2. Center for Disease Control and Prevention (2022) SARS-CoV-2 variant classifications and definitions. https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fvariants%2Fvariant-info.html . Accessed July 7, 2022
  3. Protocols.io (2020) nCoV-2019 sequencing protocol v3 (LoCost) V.3. https://www.protocols.io/view/ncov-2019-sequencing-protocol-v3-locost-bh42j8ye?version_warning=no . Accessed July 7, 2022
  4. Charre C, Ginevra C, Sabatier M, Regue H, Destras G, Brun S et al (2020) Evaluation of NGS-based approaches for SARS-CoV-2 whole genome characterisation. Virus Evol 6(2):veaa075. https://doi.org/10.1093/ve/veaa075 . Accessed July 7, 2022
  5. Febbo P (2020) How sequencing-based surveillance helps fight COVID-19. https://www.illumina.com/company/news-center/blog/sequencing-based-surveillance-helps-fight-covid-19.html . Accessed July 7, 2022
  6. Illumina Inc. (2022) COVIDSeq test (RUO Version). https://www.illumina.com/products/by-type/clinical-research-products/covidseq.html . Accessed July 7, 2022
  7. Artic Network (2022) Artic Network covid sequencing protocol. https://artic.network/ncov-2019 . Accessed July 7, 2022
  8. Illumina Inc. (2022) Illumina COVIDSeq test. https://www.illumina.com/products/by-type/ivd-products/covidseq.html . Accessed July 7, 2022

Grants

  1. T32 GM132055/NIGMS NIH HHS

MeSH Term

Humans
COVID-19
Genome, Viral
High-Throughput Nucleotide Sequencing
SARS-CoV-2

Word Cloud

Created with Highcharts 10.0.0SARS-CoV-2sequencinggenomechapternext-generationentireprocedureviralsevereacuterespiratorysyndromecoronavirus2describedSuccessfulvirusdependentuponqualityspecimenadequatecoverageup-to-dateannotationadvantagesperformingsurveillanceusingscalabilityhigh-throughputcostfullanalysisdisadvantagescanexpensiveinstrumentationlargeupfrontreagentsupplycostsincreasedtime-to-resultcomputationalneedscomplicatedbioinformaticswillprovideoverviewmodifiedFDAEmergencyUseAuthorizationgenomicalsoreferredresearchuseRUOversionSequencingVariantSurveillanceCOVID-19Next-generationVariants

Similar Articles

Cited By

No available data.